A review of the lipid-related effects of fluvastatin.
BACKGROUND
Statin therapy has been shown to significantly decrease vascular events and overall mortality in primary and secondary prevention trials. This review considers the pharmacology, nonlipid-lowering effects and clinical trial evidence of fluvastatin based on a survey of PubMed entries.


RESULTS
Recent clinical data show that treatment with fluvastatin is associated with a variety of benefits in different high-risk populations along with a good safety profile. Fluvastatin exerts non-lipid lowering-associated pleiotropic effects in both clinical and experimental studies. Furthermore, an extended-release formulation of fluvastatin with a favourable pharmacokinetic profile is available.


CONCLUSIONS
Treatment with fluvastatin offers a convenient, safe and evidence-based approach to managing dyslipidaemias and preventing vascular events.
Liberopoulos
Evagelos N
EN
Department of Internal Medicine, Medical School, University of Ioannina, Greece.
Daskalopoulou
Stella S
SS
Mikhailidis
Dimitri P
DP
Wierzbicki
Anthony S
AS
Elisaf
Moses S
MS
D003324:Coronary Artery Disease / Q000209:etiology / Q000517:prevention & control; D005229:Fatty Acids, Monounsaturated / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D000077340:Fluvastatin; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy*; D007211:Indoles / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D008055:Lipids / Q000097:blood*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D005229:Fatty Acids, Monounsaturated; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007211:Indoles; D008055:Lipids; D000077340:Fluvastatin